Barclays capital-at-risk pharma note pays 9.75% in the US

Barclays is offering a 12-month reverse convertible based on the stock of Valeant Pharmaceuticals. The high coupon is typical of shorter-term structures of this type that allow for some risk to capital


Barclays in the US has issued a 12-month structured product tied to the performance of the common stock of Valeant Pharmaceuticals International. The note will pay a fixed monthly coupon even if the price of the underlying falls below the barrier level during the monitoring period. Capital is at risk if the price of the underlying stock falls below the protection level at the close of any business day and stays below the initial level on the final valuation date.

This product is a reverse

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options


Want to know what’s included in our free membership? Click here

This address will be used to create your account

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here